Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Kura Oncology, Inc. KURA |
BLACKROCK INC BLK |
6,329,050 7.800% |
-1,605,054 (-20.23%) |
Filing History |
| 2025-02-14 5:30 pm Purchase |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
Armistice Capital, LLC | 5,800,000 7.460% |
5,800,000 (New Position) |
Filing History |
| 2025-02-14 4:42 pm Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
Paradigm BioCapital Advisors LP | 0 0.000% |
-4,331,321 (Position Closed) |
Filing History |
| 2025-02-13 8:15 pm Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,198,189 6.700% |
-2,274,154 (-30.43%) |
Filing History |
| 2025-02-13 08:57 am Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
Flynn James E | 0 0.000% |
-5,312,733 (Position Closed) |
Filing History |
| 2025-02-04 8:09 pm Purchase |
2025-01-27 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 5,912,554 7.500% |
2,504,500 (+73.49%) |
Filing History |
| 2025-02-04 8:05 pm Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 3,408,054 4.300% |
-804,292 (-19.09%) |
Filing History |
| 2025-01-08 7:42 pm Purchase |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
BLACKROCK INC BLK |
7,934,104 10.200% |
618,457 (+8.45%) |
Filing History |
| 2024-12-05 6:55 pm Purchase |
2024-11-27 | 13G | Kura Oncology, Inc. KURA |
RA Capital Management, L.P. | 4,368,998 5.600% |
4,368,998 (New Position) |
Filing History |
| 2024-11-14 4:32 pm Sale |
2024-09-30 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 4,212,346 5.400% |
-3,160,882 (-42.87%) |
Filing History |
| 2024-11-14 4:31 pm Purchase |
2024-09-30 | 13G | Kura Oncology, Inc. KURA |
Paradigm BioCapital Advisors LP | 4,331,321 5.700% |
470,003 (+12.17%) |
Filing History |
| 2024-05-02 4:34 pm Purchase |
2024-04-22 | 13G | Kura Oncology, Inc. KURA |
Paradigm BioCapital Advisors LP | 3,861,318 5.100% |
3,861,318 (New Position) |
Filing History |
| 2024-02-14 5:58 pm Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
EcoR1 Capital LLC | 7,598,797 9.990% |
960,426 (+14.47%) |
Filing History |
| 2024-02-14 09:39 am Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 7,373,228 9.900% |
3,572,245 (+93.98%) |
Filing History |
| 2024-02-13 5:23 pm Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
SUVRETTA CAPITAL MANAGEMENT, LLC | 7,472,343 9.990% |
1,095,528 (+17.18%) |
Filing History |
| 2024-02-13 5:08 pm Purchase |
2023-12-29 | 13G | Kura Oncology, Inc. KURA |
The Vanguard Group | 4,037,691 5.440% |
632,522 (+18.58%) |
Filing History |
| 2024-02-12 5:33 pm Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
Flynn James E | 5,312,733 7.150% |
938,689 (+21.46%) |
Filing History |
| 2024-01-24 2:27 pm Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
BLACKROCK INC BLK |
7,315,647 9.800% |
2,152,811 (+41.70%) |
Filing History |
| 2024-01-23 09:12 am Sale |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
STATE STREET CORP STT |
2,921,810 3.930% |
-1,524,617 (-34.29%) |
Filing History |
| 2023-09-21 4:55 pm Purchase |
2023-09-14 | 13G | Kura Oncology, Inc. KURA |
Flynn James E | 4,374,044 5.890% |
1,991,044 (+83.55%) |
Filing History |